Cargando…

MRI phenotypes in MS: Longitudinal changes and miRNA signatures

OBJECTIVE: To classify and immunologically characterize persons with MS based on brain lesions and atrophy and their associated microRNA profiles. METHODS: Cerebral T2-hyperintense lesion volume (T2LV) and brain parenchymal fraction (BPF) were quantified and used to define MRI phenotypes as follows:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hemond, Christopher C., Healy, Brian C., Tauhid, Shahamat, Mazzola, Maria A., Quintana, Francisco J., Gandhi, Roopali, Weiner, Howard L., Bakshi, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384020/ https://www.ncbi.nlm.nih.gov/pubmed/30800720 http://dx.doi.org/10.1212/NXI.0000000000000530

Ejemplares similares

Whole‐brain atrophy assessed by proportional‐ versus registration‐based pipelines from 3T MRI in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2018)

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis
por: Dastagir, Akram, et al.
Publicado: (2018)

Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines
por: Chu, Renxin, et al.
Publicado: (2018)

An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis
por: Kim, Gloria, et al.
Publicado: (2016)

Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability
por: Chu, Renxin, et al.
Publicado: (2017)

Dual‐Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI
por: Meier, Dominik S., et al.
Publicado: (2017)

Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2017)

The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis
por: Yousuf, Fawad, et al.
Publicado: (2016)

Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases
por: Hemond, Christopher C., et al.
Publicado: (2021)

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
por: Tauhid, Shahamat, et al.
Publicado: (2015)

T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis
por: Kim, Gloria, et al.
Publicado: (2015)

Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS
por: Rothhammer, Veit, et al.
Publicado: (2017)

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis
por: Chu, Renxin, et al.
Publicado: (2016)

Identification of MS-specific serum miRNAs in an international multicenter study
por: Regev, Keren, et al.
Publicado: (2018)

The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis
por: Oommen, Vinit V., et al.
Publicado: (2015)

Regional microglial activation in the substantia nigra is linked with fatigue in MS
por: Singhal, Tarun, et al.
Publicado: (2020)

Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis
por: Bakshi, Rohit, et al.
Publicado: (2016)

The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing‐Remitting Multiple Sclerosis
por: Singhal, Tarun, et al.
Publicado: (2016)

Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study
por: Singhal, Tarun, et al.
Publicado: (2019)

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
por: Lokhande, Hrishikesh, et al.
Publicado: (2022)

An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2
por: Bakshi, Rohit, et al.
Publicado: (2014)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors
por: Dell’Oglio, Elisa, et al.
Publicado: (2015)

Increased leptin and A-FABP levels in relapsing and progressive forms of MS
por: Messina, Silvia, et al.
Publicado: (2013)

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
por: Hemond, Christopher C., et al.
Publicado: (2019)

MRI activity in MS and completed pregnancy: Data from a tertiary academic center
por: Houtchens, Maria, et al.
Publicado: (2020)

COVID-19 mRNA vaccination leading to CNS inflammation: a case series
por: Khayat-Khoei, Mahsa, et al.
Publicado: (2021)

Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models
por: Chua, Alicia S., et al.
Publicado: (2015)

IL-27 Imparts Immunoregulatory Function to Human NK Cell Subsets
por: Laroni, Alice, et al.
Publicado: (2011)

COVID-19 in teriflunomide-treated patients with multiple sclerosis
por: Maghzi, Amir Hadi, et al.
Publicado: (2020)

Serum antibodies to phosphatidylcholine in MS
por: Sádaba, Maria Cruz, et al.
Publicado: (2020)

A dual modeling approach to automatic segmentation of cerebral T2 hyperintensities and T1 black holes in multiple sclerosis
por: Valcarcel, Alessandra M., et al.
Publicado: (2018)

Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
por: Sattarnezhad, Neda, et al.
Publicado: (2022)

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
por: Regev, Keren, et al.
Publicado: (2016)

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
por: Bose, Gauruv, et al.
Publicado: (2023)

Effect of Natalizumab Treatment on Circulating Plasmacytoid Dendritic Cells: A Cross-Sectional Observational Study in Patients with Multiple Sclerosis
por: Kivisäkk, Pia, et al.
Publicado: (2014)

Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
por: Holroyd, Kathryn B., et al.
Publicado: (2022)

Exploration of machine learning techniques in predicting multiple sclerosis disease course
por: Zhao, Yijun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uj87j4jtr1n7fhrjq5uu6dp2m9